Sugi Predict

Sugi Predict / Compounds / SCHEMBL2937833

SCHEMBL2937833

SCHEMBL2937833

O=C1N(c2ccc(OC(F)(F)F)cc2)C(=O)C2(CC2)N1Cc1c(N2CCCCC2)cnc2ccccc12

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ GCGR P47871 2/20 0.39
▸ IGF1R P08069 1/20 0.36
▸ LMNA P02545 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ THRB P10828 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ LIPE Q05469 2/20 0.33
▸ ENPP2 Q13822 1/20 0.33
▸ MCHR1 Q99705 6/20 0.33
▸ ACP1 P24666 1/20 0.33
▸ TRPM8 Q7Z2W7 2/20 0.32
▸ CRHBP P24387 1/20 0.32
▸ CRHR2 Q13324 1/20 0.32
▸ GBA1 P04062 1/20 0.32
▸ MGLL Q99685 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2942801 0.90 IGF1R (0.47) IGF1RLMNATP53THRBKDM4E
SCHEMBL2941190 0.87 IGF1R (0.41) IGF1R
SCHEMBL2939719 0.86 GCGR (0.41) GCGRIGF1RLIPEMCHR1
SCHEMBL2943165 0.86 IGF1R (0.52) IGF1RLMNAMAPTMCHR1
SCHEMBL2939105 0.85 GCGR (0.42) GCGRIGF1RLIPEMCHR1TRPM8
SCHEMBL2936895 0.85 GCGR (0.41) GCGRIGF1RLIPEENPP2MCHR1
SCHEMBL2936711 0.85 GCGR (0.42) GCGRIGF1RLIPEENPP2MCHR1
SCHEMBL2943023 0.84 GCGR (0.41) GCGRIGF1RMCHR1
SCHEMBL2937513 0.83 GCGR (0.42) GCGRIGF1RLIPEENPP2MCHR1
SCHEMBL2935293 0.83 GCGR (0.41) GCGRIGF1RLIPEENPP2MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825115-B2 Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-11-02 — — US disclosed
EP-1599464-B1 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2010-09-22 — — EP disclosed
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-08 — — US disclosed
US-7354933-B2 Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate AVENTIS PHARMA SA (FR) 2008-04-08 — — US disclosed
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2004-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors PRKG1, PRKACA, CMPK1 GCGR 2462/4885IGF1R 1595/4885LMNA 1988/4885
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors PRKG1, PRKACA, PRKCA GCGR 2407/4885IGF1R 962/4885LMNA 2970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.